Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed breast cancer meeting 1 of the following criteria:
• * Ductal carcinoma in situ (DCIS)
• * Invasive carcinoma
• * Stage I-III disease
• Must have undergone breast cancer surgery within the past 6 months, including any of the following:
• * Mastectomy or lumpectomy with or without radiation
• * Sentinel node and/or axillary node dissection
• * Re-excision of lumpectomy margins
• Intact contralateral breast
• * No prior radiation therapy or mastectomy
• * Prior biopsies allowed
• Hormone receptor status:
• * Estrogen and/or progesterone receptor-positive tumor by immunohistochemical staining
• PATIENT CHARACTERISTICS:
• Sex
• Female
• Menopausal status
• Postmenopausal, defined as 1 of the following:
• * At least 60 years of age
• * Less than 60 years of age and amenorrheic ≥ 12 months prior to study entry
• * Less than 60 years of age, amenorrheic for \< 12 months prior to day 1, and luteinizing hormone (LH) and follicle stimulating hormone (FSH) values within postmenopausal range
• * Less than 60 years of age, without a uterus, and LH and FSH values within postmenopausal range
• * Underwent prior bilateral oophorectomy
• * Underwent prior radiation castration AND amenorrheic for ≥ 6 months
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Not specified
• Hepatic
• Not specified
• Renal
• Not specified
• PRIOR CONCURRENT THERAPY:
• Chemotherapy
• No prior or concurrent adjuvant chemotherapy for breast cancer
• Endocrine therapy
• No prior aromatase inhibitor
• At least 6 weeks since prior and no concurrent tamoxifen
• At least 6 weeks since prior and no concurrent hormone replacement therapy
• * Concurrent low-dose, local vaginal estrogen in the form of either a conjugated estrogen ring or other similar product (e.g., Estring® or Vagifem®) allowed
• At least 6 weeks since prior and no other concurrent selective estrogen receptor modulators (e.g., raloxifene)
• Radiotherapy
• See Disease Characteristics
• Surgery
• See Disease Characteristics
• No contralateral breast implant
• Other
• Concurrent bisphosphonates allowed at the discretion of the treating oncologist
• No concurrent consumption of soy supplements
• * Concurrent routine dietary consumption of soy-containing foods allowed
• No other concurrent investigational or commercial drugs or therapies for the treatment of DCIS or invasive breast cancer